according to one source , glaxosmithkline will soon be following pfizer 's lead and significantly lopping off a chunk of its sales force for the past year or so , company after company has admitted that its roi on multiplexed sales calls multiple calls to the same practice has eroded , and company after company has quietly reacted to this erosion with measured , targeted reductions in the number of calls per physician everyone was waiting for one company , pfizer in particular , to come out publicly and admit that it wasn t changing its sales practices fast enough to protect profit growth no company wanted to be first to blink , as a unilateral move was viewed as risky now that pfizer has blinked , does this mean others will follow ? while i suspect that some execs will seriously consider using pfizer s move to try to gain a competitive sales edge , most majors are likely instead to use the move as an opportunity to do the same glaxosmithkline nyse gsk news , which has made numerous overtures in this regard search my blog to read some , is likely to be up next , followed by many others pharma new world new world pharma i hope you two enjoy a productive relationship source yahoo news for more on the topic of downsizing pharmaceutical sales forces , head over to the wonderful world of pharmagossip